Turn evidence into direction

Connect biomarkers, causal evidence, and competitive context so translational decisions move faster and with more confidence.

Start free trial

Evidence for the next indication

See how EMET supports translational teams focused on indication strategy, biomarker planning, and evidence synthesis.

Translational capabilities

Explore a range of sample prompts and representative outputs from EMET across the workflows below.

Companion diagnostic output showing biomarker thresholds, co-mutations, and enrichable patient segments.

Companion Diagnostic Biomarker Development

We're advancing a TROP2-targeting ADC into Phase II NSCLC. Define a companion diagnostic biomarker strategy: identify which TROP2 expression levels, co-mutations, and immune features best predict response, and estimate the size of the enrichable patient population.

pubmed-literaturecbioportal-mutations
Indication expansion output comparing evidence across candidate diseases and translational rationale.

Indication Expansion

Given that VEGF pathway inhibitors are approved in oncology, what evidence supports their investigation in age-related macular degeneration or diabetic retinopathy?

pubmed-literatureproteinatlas-proteingene-resolveropenfda-adversedrug-resolver
Drug repurposing output showing ranked candidates from transcriptomic reversal analysis.

Transcriptomics-Driven Drug Repurposing

We have a transcriptomic disease signature from ALS patient motor neurons (top 100 up/downregulated genes). Find FDA-approved drugs that reverse this signature using LINCS L1000 data, cross-check against neurological target safety, and rank by clinical precedent in neurodegenerative disease.

clinicaltrials-searchdrug-resolversafety-target-validatorgeo-datasetsl1000fwd-signatures
Causal inference output showing Mendelian randomization, eQTL mapping, and GWAS overlap.

Causal Inference / GWAS

Use Mendelian randomization to test whether genetically elevated IL-6 signalling raises type 2 diabetes risk, map the lead IL6 eQTLs across tissues, and check whether any colocalize with T2D/glycemic GWAS loci.

EpiGraphDB Causal (MR)GWAS CatalogGTEx eQTLPan-UKBB GWASGeneBASS Exomes
Competitive clinical landscape output summarizing active KRAS G12C trials and key differentiators.

Competitive Clinical Landscape Intelligence

Give me a comprehensive competitive intelligence report on KRAS G12C inhibitors. Cover: all active clinical trials by phase and sponsor, publication output over the past 3 years, patent filing trends, and differentiation between sotorasib, adagrasib, and emerging programmes.

competitive-intelligenceclinicaltrials-searchopenalex-literatureicite-citationsktmine-patentsdrug-resolverchembl-bioactivitiesoncokb-actionabilitycbioportal-mutationsdgidb-interactions
Safety and toxicity output showing adverse events, drug interactions, and pharmacogenomic dosing factors.

Safety & Toxicity Profiling

What are the known adverse events and drug interactions for warfarin, and how do common genetic variants in CYP2C9 and VKORC1 influence its toxicity and dosing safety?

openfda-adversegtex-expressionpharmgkb-pgxfrdb-reactionsgtopdb-targets

Frequently asked questions

Drug programs fail when biology is misunderstood. EMET exists to close that gap — before it closes your pipeline.

Start free trial